Anetumab Ravtansine

Phase 3Biologic

Anetumab Ravtansine is one of 196 biologic programs targeting Malignant Pleural Mesothelioma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

195

Competitors

Pipeline

Status by Indication[3][1]

Indication

Malignant Pleural MesotheliomaActive, not recruiting

Pleural MesotheliomaActive, not recruiting

MesotheliomaActive, not recruiting

Lung AdenocarcinomaActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Pancreatic CancerActive, not recruiting

Fallopian Tube Endometrioid AdenocarcinomaActive, not recruiting

Malignant Pleural MesotheliomaPhase 2

Active, not recruiting

Pleural MesotheliomaPhase 1/Phase 2

Active, not recruiting

MesotheliomaPhase 3

Active, not recruiting

Lung AdenocarcinomaPhase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 1

Active, not recruiting

Pancreatic CancerPhase 2

Active, not recruiting

Fallopian Tube Endometrioid AdenocarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Anetumab Ravtansine

Bayer

Phase 3

1 2

Yervoy

Bristol-Myers Squibb

Preclinical

31 3

Gemzar

GGynecologic Oncology Group

Preclinical

72 4

PORTRAZZA

Eli Lilly

Preclinical

8 5

Lenvima

Eisai

Preclinical

6 6

Gilotrif

Boehringer Ingelheim

Preclinical

12 7

Ofev

Boehringer Ingelheim

Preclinical

7 8

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—9

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Fallopian Tube Endometrioid Adenocarcinoma

NCT03587311

Q1 2027

Phase 1Active, not recruiting

Pancreatic Cancer

NCT03816358

Phase 1/2Active, not recruiting

Pleural Mesothelioma

NCT03126630

Clinical

Trials by Indication[1]

Pancreatic Cancer2 trials

Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer

Completed·YYale University·Phase 2·NCT03023722·18 enrolled

Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT03816358·74 enrolled

Pleural Mesothelioma1 trial

Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1/2·NCT03126630·49 enrolled

Non-Small Cell Lung Cancer1 trial

Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer

Terminated·MMayo Clinic·Phase 1·NCT03455556·1 enrolled

Lung Adenocarcinoma1 trial

Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung Adenocarcinoma

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT02839681·2 enrolled

Advanced Solid Tumors1 trial

Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors

Completed· Bayer logo

Bayer·Phase 1·NCT03102320·173 enrolled

5 more indications

Liposomal Doxorubicin1 trial

Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer

Completed· Bayer logo

Bayer·Phase 1·NCT02751918·65 enrolled

Malignant Pleural Mesothelioma1 trial

Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)

Completed· Bayer logo

Bayer·Phase 2·NCT02610140·248 enrolled

Interaction1 trial

Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole

Completed· Bayer logo

Bayer·Phase 1·NCT02824042·63 enrolled

Renal Impairment1 trial

Phase I Study of Anetumab Ravtansine in Hepatic or Renal Impairment

Completed· Bayer logo

Bayer·Phase 1·NCT02696642·54 enrolled

Fallopian Tube Endometrioid Adenocarcinoma1 trial

A Randomized Phase 2 Study of Bevacizumab and Either Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant or Platinum Refractory Ovarian Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT03587311·96 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Anetumab Ravtansine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Anetumab Ravtansine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Anetumab Ravtansine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bayer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: Bayer

Anetumab Ravtansine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Trials by Indication[1]

Pancreatic Cancer2 trials

Pleural Mesothelioma1 trial

Non-Small Cell Lung Cancer1 trial

Lung Adenocarcinoma1 trial

Advanced Solid Tumors1 trial

Liposomal Doxorubicin1 trial

Malignant Pleural Mesothelioma1 trial

Interaction1 trial

Renal Impairment1 trial

Fallopian Tube Endometrioid Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News